EFFICACY OF SINEMET CR4 IN SUBGROUPS OF PATIENTS WITH PARKINSONS-DISEASE
EFFICACY OF SINEMET CR4 IN SUBGROUPS OF PATIENTS WITH PARKINSONS-DISEASE
复制标题
DOI：
10.1136/jnnp.52.1.83
复制
发表时间：
1989-01-01
影响因子：
11
通讯作者：
INGENITO, AM
中科院分区：
文献类型：
--
作者：
FACTOR, SA;SANCHEZRAMOS, JR;INGENITO, AM
在一项针对帕金森病患者的开放标签交叉研究中，比较了Sinemet CR4（50/200）与标准Sinemet（25/100）的疗效。所有患者均出现给药失败，11例患者出现运动障碍。在每个治疗期结束时，对统一帕金森病、Hoehn和Yahr评分、Schwab和England评分、每天服药小时数、每天出现运动障碍的小时数、左旋多巴的每日剂量和每天的剂量进行监测，并对结果进行比较。在整个组中，CR4和标准Sinemet治疗期间这些参数的唯一显著差异是每天运动障碍小时数的减少。专门检查了两个CR4应答亚组。第一个亚组的特点是每天接受CR4治疗的时间显著增加。与其他患者相比，这些患者帕金森病发病年龄较大，病程和波动时间较短。第二个亚组的特征是使用标准的Sinemet治疗存在运动障碍，并且使用CR4治疗每天运动障碍的小时数显着减少。两个亚组在服用CR4时都需要更高的左旋多巴日剂量。结论是，CR4可能有助于增加帕金森病患者亚组每天的睡眠时间，这些患者波动较小。它也可能有助于减少每天运动障碍的小时数。
The efficacy of Sinemet CR4 (50/200) was compared to standard Sinemet (25/100) in an open label crossover study in patients with Parkinson''s disease. All patients experienced end of dose failure and 11 had dyskinesia. Unified Parkinson''s disease, Hoehn and Yahr, Schwab and England scores, number of hours on per day, number of hours of dyskinesia per day, daily dose of levodopa, and number of doses per day were monitored at the end of each treatment period and the results compared. The only significant difference in these parameters between the CR4 and standard Sinemet treatment periods in the entire group was a decrease in hours of dyskinesia per day. Two subgroups of CR4 responders were specifically examined. The first subgroup was characterised by a significant increase in on time per day with CR4 therapy. These patients had an older age of onset of Parkinson''s disease and a shorter duration of disease and fluctuations than the rest of the patients. The second subgroup was characterised by the presence of dyskinesia with standard Sinemet therapy and a significant decrease in hours of dyskinesia per day with CR4 therapy. Both subgroups required a significantly higher daily dose of levodopa while on CR4. It is concluded that CR4 may be useful in increasing hours on per day in subgroups of Parkinson''s disease patients who have less severe fluctuations. It may also be useful in decreasing the number of hours of dyskinesia per day.